Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. SPY

Go back to Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases

Baird on Mirum Pharmaceuticals (MIRM): 'we expect upside for the stock'

October 12, 2026 9:34 AM EDT

Baird analyst Brian Skorney reiterated an Outperform rating and $130.00 price target on Mirum Pharmaceuticals (NASDAQ: MIRM).

The analyst comments "Incrementally positive on EXPAND success. Mirum announced the Ph3 EXPAND basket study of maralixibat in additional cholestatic indications, about half biliary atresia patients,... More